Novartis AG on Thursday scrapped the $1 billion sale of U.S. generic
pill and skin drug assets to India's Aurobindo Pharma Ltd as
regulators balked, setting back the Swiss drugmaker's shift to more
profitable medicines.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/novartis-scraps-sale-of-assets-including-covid-19-hopeful-to-indias-aurobindo/articleshow/74944483.cms
No comments:
Post a Comment